绿康生化(002868) - 2021 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2021 was ¥173,844,094.41, a decrease of 2.36% compared to ¥178,051,590.46 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was ¥6,565,087.10, down 81.69% from ¥35,863,013.15 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥6,658,132.49, a decrease of 77.77% compared to ¥29,946,701.23 in the same period last year[22]. - The net cash flow from operating activities was -¥18,353,447.83, a decline of 140.18% from ¥45,680,267.40 in the previous year[22]. - Basic earnings per share were ¥0.04, down 82.61% from ¥0.23 in the same period last year[22]. - Operating costs increased by 21.95% to ¥132,288,616.56 from ¥108,480,530.66 year-on-year[38]. - Research and development expenses rose by 23.79% to ¥12,579,486.73, up from ¥10,161,593.02 in the previous year[38]. - The company reported a significant increase in financial expenses, which rose by 324.42% to ¥1,024,849.50, primarily due to exchange losses[38]. - The company reported a total non-operating loss of ¥3,250,284.42 after tax effects and minority interests[26]. - The company reported a total revenue of 600 million yuan for the first half of 2021, with a year-on-year increase of 86.82%[102]. Assets and Liabilities - Total assets at the end of the reporting period were ¥999,216,099.69, an increase of 2.75% from ¥972,502,779.28 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company were ¥750,236,905.08, a decrease of 1.95% from ¥765,148,250.51 at the end of the previous year[22]. - The company's current assets decreased to RMB 195,356,705.83 from RMB 304,576,512.59, representing a decline of about 36%[147]. - Total liabilities increased to RMB 244,263,204.32 from RMB 202,559,099.70, which is an increase of about 20.5%[148]. - The company's short-term borrowings surged to RMB 67,665,494.99 from RMB 5,005,270.83, reflecting a significant increase of approximately 1255%[148]. - The total equity attributable to the parent company decreased to RMB 750,236,905.08 from RMB 765,148,250.51, a decline of about 1.9%[149]. Business Operations - The company operates in three main business segments: animal health, plant protection, and food additives, with no changes in its primary business activities during the reporting period[29]. - The company has established stable partnerships with major clients, including global and domestic leaders in the animal health and agriculture sectors[35]. - The company has been recognized as a national high-tech enterprise and has received multiple awards for its technological innovations and patents, totaling 16 invention patents and 15 utility model patents as of mid-2021[31]. - The company emphasizes product quality, adhering to GMP standards, and has successfully passed various international inspections, including those by the FDA and Australian authorities[34]. - The company has developed core production technologies, including spray drying and fermentation control, ensuring product quality and market adaptability[32]. Risk Management - The company has outlined potential risks and countermeasures in its management discussion and analysis section[4]. - The company faces risks from major customer procurement fluctuations, which could significantly impact revenue and profitability[62]. - The company is addressing environmental risks by implementing wastewater treatment systems and monitoring equipment to comply with environmental regulations[64]. - The company has approved a foreign exchange hedging plan to mitigate risks from currency fluctuations, with a maximum amount of USD 5 million for hedging activities[65]. - The company plans to invest up to 30 million yuan in commodity futures hedging to mitigate raw material price volatility risks from January 1, 2021, to December 31, 2021[66]. Environmental and Social Responsibility - In the first half of 2021, the company reported a chemical oxygen demand (COD) discharge concentration of 165.002 mg/L, well below the standard limit of 350 mg/L[84]. - The ammonia nitrogen discharge concentration was recorded at 4.617 mg/L, significantly lower than the regulatory standard of 35 mg/L[84]. - The company invested a total of 8.347 million yuan in environmental equipment upgrades and training in the first half of 2021[84]. - The company’s charity foundation donated a total of 33,400 yuan to support 17 impoverished families in early 2021[86]. - The foundation also provided 6,000 yuan in living expenses for children of deceased employees during the first half of 2021[86]. Future Outlook - The company provided a positive outlook for the second half of 2021, projecting a revenue growth of 20% to 30% based on current market trends and user acquisition strategies[91]. - New product launches are expected to contribute an additional 200 million RMB in revenue by the end of 2021, focusing on innovative biopharmaceutical solutions[91]. - The company is exploring potential mergers and acquisitions to strengthen its market position, with a budget of 500 million RMB earmarked for strategic investments[91]. - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[177]. Shareholder and Corporate Governance - The company plans to issue convertible bonds to raise up to CNY 305 million, with the investment project total adjusted to CNY 430.686 million[115]. - The company has committed to repurchase shares if the stock price remains below the latest audited net asset value for 20 consecutive trading days within three years post-listing[92]. - The company will adhere to the latest regulations from the China Securities Regulatory Commission regarding compensation measures if commitments are violated[93]. - The company has established a framework for repurchase and stabilization of stock prices to ensure investor confidence[92]. - The company has no significant litigation or arbitration matters during the reporting period[100].